A mechanistic digital twin model for epigenetic therapy optimization in triple-negative breast cancer
- 1Dana-Farber Cancer Institute
Abstract
Epigenetic therapies offer a promising approach to cancer treatment by modulating chromatin states that govern tumor cell identity, plasticity and therapeutic response. However, predicting and optimizing the effects of such interventions remains challenging. Here, we developed a digital twin framework that integrates mechanistic models of chromatin regulation, in vitro cell-state and treatment response data, and pharmacokinetics to simulate tumor progression and therapeutic response. We applied this framework to triple-negative breast cancer (TNBC), an aggressive disease in which chromatin dysregulation contributes to tumor progression, and investigated combination treatment with an EZH2 inhibitor promiting chromatin opening and an AKT inhibitor, which together enhance expression of GATA3 and BMF. Parameterized and validated using in vitro treatment response data, the model enables in silico clinical trials of alternative combination regimens and treatment schedules. These simulations identify regimens that achieve comparable therapeutic effects to reference schedules while substantially reducing cumulative drug exposure. We further demonstrated the digitan twin's ability of identifying personalized therapeutic strategies by incorporating patient-specific treatment-response data. Our work establishes a mechanistic digital twin framework for predicting tumor responses to chromatin-modifying therapies and provides a quantitative approach for optimizing treatment combinations and schedules across diverse cancer contexts.
Related
- 683 Single-cell RNA-seq analysis of 9464D-GD2 neuroblastoma reveals immune remodeling after anti-CD40 and epigenetic modifier inhibitor therapy
- Autophagy as an adaptive resistance mechanism to epigenetic therapy in cancer.
- Epigenetic and RNA control of cancer stem cell plasticity and therapy resistance
- Safety of concurrent immune checkpoint inhibitor therapy during postoperative radiotherapy for triple-negative breast cancer: A preliminary retrospective analysis
- Is a Repeat Head CT Scan Necessary After an Initial Negative Scan in Head Trauma Patients on DOAC Therapy in the Emergency Department?
BibTeX
@misc{bruno2026mechanistic,
title = {{A mechanistic digital twin model for epigenetic therapy optimization in triple-negative breast cancer}},
author = {S. Bruno and A. Indeglia and S. Lichterfeld and A. E. Schade and K. Cichowski and F. Michor},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.11.750942},
url = {https://www.biorxiv.org/content/10.64898/2026.09.11.750942v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - A mechanistic digital twin model for epigenetic therapy optimization in triple-negative breast cancer
AU - S. Bruno
AU - A. Indeglia
AU - S. Lichterfeld
AU - A. E. Schade
AU - K. Cichowski
AU - F. Michor
PY - 2026
DA - 2026/09/11
PB - bioRxiv
DO - 10.64898/2026.09.11.750942
UR - https://www.biorxiv.org/content/10.64898/2026.09.11.750942v1
AB - Epigenetic therapies offer a promising approach to cancer treatment by modulating chromatin states that govern tumor cell identity, plasticity and therapeutic response. However, predicting and optimizing the effects of such interventions remains challenging. Here, we developed a digital twin framework that integrates mechanistic models of chromatin regulation, in vitro cell-state and treatment response data, and pharmacokinetics to simulate tumor progression and therapeutic response. We applied this framework to triple-negative breast cancer (TNBC), an aggressive disease in which chromatin dysregulation contributes to tumor progression, and investigated combination treatment with an EZH2 inhibitor promiting chromatin opening and an AKT inhibitor, which together enhance expression of GATA3 and BMF. Parameterized and validated using in vitro treatment response data, the model enables in silico clinical trials of alternative combination regimens and treatment schedules. These simulations identify regimens that achieve comparable therapeutic effects to reference schedules while substantially reducing cumulative drug exposure. We further demonstrated the digitan twin's ability of identifying personalized therapeutic strategies by incorporating patient-specific treatment-response data. Our work establishes a mechanistic digital twin framework for predicting tumor responses to chromatin-modifying therapies and provides a quantitative approach for optimizing treatment combinations and schedules across diverse cancer contexts.
ER -